In this article
Regeneron
agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White House said on Thursday.
The biotech company will also offer the first hearing-loss gene therapy for free to eligible U.S. patients following regulatory approval of the product earlier Thursday.
Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump. Those deals are part of his “most favored nation” effort to tie U.S. drug prices to the lowest ones in other developed nations.
